MX2010005488A - Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina. - Google Patents

Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.

Info

Publication number
MX2010005488A
MX2010005488A MX2010005488A MX2010005488A MX2010005488A MX 2010005488 A MX2010005488 A MX 2010005488A MX 2010005488 A MX2010005488 A MX 2010005488A MX 2010005488 A MX2010005488 A MX 2010005488A MX 2010005488 A MX2010005488 A MX 2010005488A
Authority
MX
Mexico
Prior art keywords
histamine
receptor
cycloalkyloxy
compounds
rocycloalky
Prior art date
Application number
MX2010005488A
Other languages
English (en)
Inventor
Michael A Letavic
Emily M Stocking
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40297867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005488(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2010005488A publication Critical patent/MX2010005488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ciertos compuestos de cicloalquiloxi y heterocicloalquiloxipiridin a son moduladores del receptor H3 de histamina útiles en el tratamiento de las enfermedades mediadas por el receptor H3 de histamina.
MX2010005488A 2007-11-20 2008-11-17 Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina. MX2010005488A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98924607P 2007-11-20 2007-11-20
PCT/US2008/083764 WO2009067401A1 (en) 2007-11-20 2008-11-17 Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor

Publications (1)

Publication Number Publication Date
MX2010005488A true MX2010005488A (es) 2010-06-01

Family

ID=40297867

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005488A MX2010005488A (es) 2007-11-20 2008-11-17 Compuestos de cicloalquiloxi y heterocicloalquiloxipiridina como moduladores del receptor h3 de histamina.

Country Status (23)

Country Link
US (1) US8883776B2 (es)
EP (1) EP2222664B1 (es)
JP (1) JP5498390B2 (es)
KR (1) KR101546712B1 (es)
CN (2) CN105712977B (es)
AR (2) AR069387A1 (es)
AU (1) AU2008326561B2 (es)
BR (1) BRPI0820481A2 (es)
CA (1) CA2706328C (es)
CL (1) CL2008003465A1 (es)
CO (1) CO6210700A2 (es)
CR (1) CR11529A (es)
EA (1) EA018582B1 (es)
EC (1) ECSP10010190A (es)
HK (1) HK1147994A1 (es)
MX (1) MX2010005488A (es)
MY (1) MY158253A (es)
NI (1) NI201000086A (es)
NZ (1) NZ584998A (es)
TW (1) TWI491604B (es)
UA (1) UA103468C2 (es)
WO (1) WO2009067401A1 (es)
ZA (1) ZA201004334B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
ATE554081T1 (de) * 2007-09-06 2012-05-15 Glaxo Group Ltd Piperazinderivate mit affinität zum histamin-h3- rezeptor
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8691804B2 (en) * 2008-05-08 2014-04-08 Evotec Ag Azetidines and cyclobutanes as histamine H3 receptor antagonists
PL3216784T3 (pl) * 2009-03-18 2019-07-31 Janssen Pharmaceutica Nv Sposób wytwarzania modulatorów receptorów histaminowych H3
CA2774981A1 (en) * 2009-09-21 2011-03-24 Vanderbilt University O-benzyl nicotinamide analogs as mglur5 positive allosteric modulators
BR112014000290B1 (pt) 2011-07-07 2022-05-10 Gilead Sciences, Inc. Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE817911C (de) 1947-12-16 1951-10-22 Chem Fab Tempelhof Preuss & Te Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden
JPS4420347Y1 (es) 1966-05-31 1969-09-01
JPS4637595Y1 (es) 1967-02-18 1971-12-25
BE726551A (es) 1968-01-22 1969-06-16
ES436109A1 (es) 1974-04-04 1977-01-01 Christiaens Sa A Procedimiento para la preparacion de nuevos derivados de pi-ridina.
EP0089153B1 (en) 1982-03-17 1986-09-24 Smith Kline & French Laboratories Limited Pyridine derivatives
GB8311443D0 (en) 1983-04-27 1983-06-02 Smith Kline French Lab Chemical compounds
GB8320505D0 (en) 1983-07-29 1983-09-01 Smith Kline French Lab Chemical compounds
GB8332091D0 (en) 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
JPS61149119A (ja) 1984-12-22 1986-07-07 旭光学工業株式会社 検眼用試験枠
US4792547A (en) 1985-12-26 1988-12-20 Hokuriku Pharmaceutical Co., Ltd. Pyrazine-2-carboxamide derivatives useful in treating allergic disease
JPH0637595B2 (ja) 1986-08-06 1994-05-18 日本ペイント株式会社 陰極電着塗料組成物
GB9025828D0 (en) 1990-11-28 1991-01-09 Shell Int Research Herbicidal carboxamide derivatives
JP3354271B2 (ja) 1993-02-25 2002-12-09 三共株式会社 ピリジルオキシアミド誘導体
EP0761654B1 (en) 1995-08-24 2003-06-18 Basf Aktiengesellschaft Isoxazole- and isothiazole-5-carboxamide derivatives, their preparation and their use as herbicides
DE69627709T2 (de) 1995-12-28 2004-02-26 Kureha Kagaku Kogyo K.K. N-(unsubstituierte oder substituierte)-4-substituierte-6-(unsubstituierte oder substituierte)phenoxy-2-pyridincarboxamide oder -thiocarboxamide, verfahren zu deren herstellung sowie herbizide
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
BR0008965A (pt) 1999-02-26 2002-02-26 Merck & Co Inc Compostos de sulfonamida e seus usos
IL146582A0 (en) 1999-05-21 2002-07-25 Biovitrum Ab Novel compounds, their use and preparation
US6399607B1 (en) 1999-07-02 2002-06-04 Research Foundation-State University Of New York Aminomethylene amide analogs of pyrazinamide with intracellular antimycobacterial activity against pyrazinamide-resistant mycobacteria combined with a rifamycin
DE10023492A1 (de) 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
JP2002322163A (ja) 2001-04-20 2002-11-08 Sumitomo Pharmaceut Co Ltd ピペラジン誘導体
US7067507B2 (en) * 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
PL367205A1 (en) 2001-06-15 2005-02-21 Yamanouchi Pharmaceutical Co, Ltd. Phenylpyridine carbonyl piperazine derivative
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
MXPA04004177A (es) 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de amida como inhibidores de la glicogeno cintasa cinasa 3-beta.
BR0213792A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
CA2474214A1 (en) 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
GB0206219D0 (en) 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
JP2006512280A (ja) 2002-03-27 2006-04-13 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
GB0209715D0 (en) 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US20040110802A1 (en) 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1554260A1 (en) * 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
EP1558595B1 (en) 2002-10-23 2009-11-25 Janssen Pharmaceutica N.V. Piperazinyl and diazapanyl benzamides and benzthioamides
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
CA2529790A1 (en) 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
MXPA06001053A (es) 2003-07-29 2006-04-11 Novo Nordisk As Piridazinil-piperazinas y su uso como ligandos del receptor de histamina h3.
WO2005023247A1 (en) 2003-09-03 2005-03-17 Smithkline Beecham Corporation Compounds and methods
GB0324159D0 (en) * 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CN1972914A (zh) 2004-03-31 2007-05-30 詹森药业有限公司 作为组胺h3受体配合体的非咪唑杂环化合物
AU2005231375A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3 receptor modulators
GB0514812D0 (en) * 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
SI1948607T1 (sl) 2005-09-16 2010-07-30 Janssen Pharmaceutica Nv Ciklopropil amini kot modulatorji histaminskega H3 receptorja
WO2007075629A2 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists
EP1966143A2 (en) 2005-12-21 2008-09-10 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
WO2007108936A2 (en) 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
MX2008015365A (es) 2006-05-30 2008-12-16 Janssen Pharmaceutica Nv Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
CA2656072A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzamide modulators of the histamine h3 receptor
US20090131417A1 (en) * 2007-11-20 2009-05-21 Letavic Michael A Substituted pyridyl amide compounds as modulators of the histamine h3 receptor

Also Published As

Publication number Publication date
UA103468C2 (ru) 2013-10-25
BRPI0820481A2 (pt) 2015-06-16
AR069387A1 (es) 2010-01-20
CR11529A (es) 2012-10-25
CO6210700A2 (es) 2010-10-20
CA2706328A1 (en) 2009-05-28
CN105712977A (zh) 2016-06-29
JP5498390B2 (ja) 2014-05-21
NZ584998A (en) 2012-08-31
JP2011503233A (ja) 2011-01-27
AU2008326561B2 (en) 2013-12-05
KR20100098636A (ko) 2010-09-08
US8883776B2 (en) 2014-11-11
HK1147994A1 (en) 2011-08-26
CL2008003465A1 (es) 2009-03-06
WO2009067401A1 (en) 2009-05-28
TW200936579A (en) 2009-09-01
MY158253A (en) 2016-09-30
EP2222664A1 (en) 2010-09-01
ECSP10010190A (es) 2010-06-29
EA018582B1 (ru) 2013-09-30
NI201000086A (es) 2011-03-17
CA2706328C (en) 2016-04-19
ZA201004334B (en) 2011-10-26
AR110977A2 (es) 2019-05-22
US20090131415A1 (en) 2009-05-21
AU2008326561A1 (en) 2009-05-28
EP2222664B1 (en) 2014-10-29
TWI491604B (zh) 2015-07-11
CN101868454A (zh) 2010-10-20
KR101546712B1 (ko) 2015-08-24
EA201070637A1 (ru) 2010-12-30
CN105712977B (zh) 2021-06-29

Similar Documents

Publication Publication Date Title
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
MY146506A (en) Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
UA96424C2 (ru) Циклопропил амины как модуляторы н3 рецепторов гистамина
EA201171367A1 (ru) Винилиндазолильные соединения
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
AP2011005637A0 (en) Carbazole compounds and therapeutic uses of the compounds.
MX2009012228A (es) Compuesto de triazolil aminopirimidina.
UA95247C2 (ru) Пиримидиновые соединения как модуляторы рецептора серотонина
EP2365815A4 (en) EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
MY158253A (en) Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine h3 receptor
MX2009007336A (es) Indazoles substituidos con 5-furopiridinona.
MX2009009364A (es) Compuestos de indol y benzotiofeno como moduladores del receptor de histamina h3.
MX2009012233A (es) Compuestos de triazolil aminopirimidina.
WO2008124524A3 (en) Aryl sulfonamide compounds as modulators of the cck2 receptor
ZA200705490B (en) Substituted benzimidazoles for treatment of histomoniasis
UA95803C2 (ru) Замещенные пиридиламидные соединения как модуляторы гистаминового н3-рецептора
UA29848U (uk) Застосування системної реконструктивної терапії як способу лікування мігрені
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
TW200744607A (en) Pyrimidine compounds as serotonin receptor modulators
UA29770U (ru) Применение мигрепина как вещества с противоболевыми свойствами
UA37933U (ru) Применение амкесола как вещества с противовоспалительными свойствами
UA36194U (en) Use of quercetin as hepatoprotector
MX2010003373A (es) Moduladores de receptores muscarinicos.

Legal Events

Date Code Title Description
FG Grant or registration